3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
2
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
36
Prostatic Neoplasms, Castration-Resistant
5
Neoplasm Metastasis
5
Metastatic Castration-Resistant Prostate Cancer
4
Neoplasms
3
Small Cell Lung Carcinoma
2
Prostatic Diseases
2
Prostate Adenocarcinoma
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sleep Initiation and Maintenance Disorders
1
Recurrence
1
Prostate Cancer Metastatic
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Neoadjuvant Therapy
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate-Resistant Prostate Cancer
1
Mesothelioma, Malignant
1
Melanoma
1
Interventions
darolutamide
3
Pluvicto
3
Docetaxel
3
testosterone 17 beta-cypionate
2
sipuleucel-T
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
ebastine
1
cabozantinib
1
cabazitaxel
1
Standard of Care
1
Prednisone
1
Prednisolone
1
PSMA-617
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-resistant Prostate Cancer
×
enzalutamide
×
Clear all
NCT06228053
2026-06-02
SYNERGY-201
Syntrix Biosystems, Inc.
Phase 2
Recruiting
53 enrolled